Molecular characteristics and antimicrobial susceptibility profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in Korea: Implications for novel β-lactam therapy.

Authors

Yoon Hyun Sung, Seung Min Park, Hak Jun Lee, Young Kyung Yoon

Published in

Journal of global antimicrobial resistance. Jul 08, 2026. Epub Jul 08, 2026.

Abstract

This study investigated the molecular epidemiology, cross-resistance to novel antibiotics, and clonal distribution of carbapenem-resistant Pseudomonas aeruginosa (CRPA) clinical isolates.
Forty-three CRPA isolates were collected from sterile clinical specimens in the Republic of Korea (ROK) between 2015 and 2025. Susceptibility to 14 antibiotics was assessed in vitro by broth microdilution. Carbapenem-resistance mechanisms were characterized by using polymerase chain reaction (PCR), real-time quantitative reverse transcription PCR (RT-qPCR), and sequencing. Clonal diversity and epidemiological trends were examined by multilocus sequence typing (MLST).
Among the 43 CRPA isolates, the susceptibility rates were 88.4% for both aztreonam-avibactam and cefiderocol, compared with 46.5% for ceftolozane-tazobactam and 39.5% for ceftazidime-avibactam. Among the 22 difficult-to-treat resistance (DTR) P. aeruginosa isolates, susceptibility rates were 77.3% for aztreonam-avibactam and 86.4% for cefiderocol. Carbapenemase genes were detected in 46.5% of isolates, predominantly bla_NDM (41.9%). Porin loss and efflux pump overexpression were observed in 83.7% and 23.3% of isolates, respectively. Among the 22 P. aeruginosa isolates non-susceptible to both ceftolozane-tazobactam and ceftazidime-avibactam, 90.9% and 77.3% remained susceptible to aztreonam-avibactam and cefiderocol, respectively. MLST identified 12 sequence types (STs), with predominance of ST773 and ST644, both carrying bla_NDM.
CRPA exhibited multifactorial resistance driven by oprD disruption and bla_NDM carriage within a diverse clonal structure dominated by ST773 and ST644. Aztreonam-avibactam and cefiderocol showed promising activity, supporting their role as critical therapeutic options.

PMID:
42419643
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.